Mycoplasma Infections Workup
- Author: Ken B Waites, MD; Chief Editor: Michael Stuart Bronze, MD more...
Consider the possibility of infection with M pneumoniae in patients of any age who present with respiratory tract infections. Laboratory investigation should focus on both the clinical illness (eg, tracheobronchitis vs pneumonia) and the many possible infectious etiologies that can cause clinically similar manifestations. The extent of laboratory investigation also should reflect the severity of the illness and whether the illness warrants hospitalization.[11, 12]
In as many as half of all cases of community-acquired pneumonias, the microbiological etiology is never determined, despite appropriate laboratory testing. The typical mild illness caused by M pneumoniae in otherwise healthy persons may not warrant a comprehensive microbiological investigation because empiric treatment with oral antimicrobials can cover M pneumoniae and most other bacterial agents that produce similar illnesses.
Twenty-five percent of patients develop leukocytosis; the rest have leukocyte counts within the reference range.
Thirty percent of patients have an elevated erythrocyte sedimentation rate.
Cellular response of sputum is mononuclear, with no bacteria visible with Gram staining.
About 75% of patients have a cold agglutinin titer of at least 1:32 by the second week of illness, disappearing by 6-8 weeks. This is not a specific test for M pneumoniae infection but the greater the cold agglutinin titer is (>1:64) in a patient with community-acquired pneumonia, the more likely the cold agglutinins are due to M pneumoniae. No specific abnormalities of hepatic or renal function are likely to occur.[13, 14, 12]
To confirm mycoplasmal respiratory tract infection, culture, molecular-based tests, and/or serological tests are necessary.
Respiratory tract specimens suitable for culture include throat swabs, sputum, tracheal aspirates, bronchial lavage fluid, pleural fluid, or lung biopsy tissue, depending on the patient's clinical condition.
Mycoplasmal organisms have fastidious growth requirements and are often difficult and slow to grow in vitro. Take care during specimen collection to inoculate into a suitable transport medium (eg, SP4 broth or universal transport medium), at the bedside whenever possible, and to not allow desiccation. Clinicians advise freezing at -70°C if specimens cannot be transported to the diagnostic laboratory immediately after collection.
Growth in culture is slow, requiring 3 weeks or longer in some cases, and the culture is not extremely sensitive for detecting M pneumoniae infection. The culture medium is often unavailable except from specialized reference laboratories. If culture is attempted, alternative procedures including serology and/or molecular-based nucleic acid amplification tests should also be performed.
Physicians use serology most frequently to confirm M pneumoniae infection even though these tests suffer from significant problems.
Many clinicians prefer enzyme-linked immunosorbent assays to the older, less sensitive complement fixation assays and nonspecific cold agglutinin titers. These types of tests are widely available through commercial reference laboratories.
Because primary infection does not guarantee protective immunity against future infections and residual immunoglobulin G (IgG) may remain from earlier encounters with the organism, experts have launched a great impetus to develop sensitive and specific tests that can differentiate between acute and remote infection.
Definitive diagnosis requires seroconversion documented by paired specimens obtained 2-4 weeks apart. Although some researchers purport that single-titer immunoglobulin M (IgM) or immunoglobulin A (IgA) assays reveal current infection, IgM may persist for up to several months in some people, and many adults may not mount a detectable IgM response. Therefore, relying on a single serological test can be clinically misleading, and experts recommend basing diagnosis of acute infection on seroconversion measured simultaneously in assays for both IgM and IgG. Use of serology for diagnosis of mycoplasmal infection is valid only if the patient has a satisfactory capacity of the humoral immune system to mount an antibody response.
Rapid diagnostic enzyme-linked immunosorbent assays
One of the most significant advances in recent years for the diagnosis of M pneumoniae respiratory tract infections is the development of qualitative, rapid, single-specimen, membrane-based enzyme-linked immunosorbent assays that are readily adaptable to the primary care physician's office laboratory.
The Remel IgG/IgM Antibody Test System (Thermo-Fisher) measures both IgG and IgM simultaneously.
The Meridian ImmunoCard (Meridian Bioscience, Inc.) measures only IgM.
Physicians can perform both tests without special expertise or equipment, and they can interpret the results in approximately 10 minutes, eliminating the need for collection of paired sera for later antibody measurement, although erroneous results are sometimes obtained when only single serum samples are analyzed.[15, 16]
Both tests have a moderate complexity classification under the Clinical Laboratory Improvement Amendment (CLIA), allowing many physicians to offer serologic assays for M pneumoniae antibodies as a point-of-care test so that it can be used to direct patient management.
Such single-specimen assays have limitations as described above; perhaps the most practical use for the IgM ImmunoCard is when an acute infection with M pneumoniae is suspected in children and young adults.
Researchers have developed molecular-based systems for detection of M pneumoniae using polymerase chain reaction (PCR) or other technologies. A variety of gene targets have been described for PCR assays to detect M pneumoniae in clinical specimens. Traditional PCR is gradually being replaced by quantitative real-time PCR assays. Recent publications indicate that the CARDS toxin gene is more sensitive for M pneumoniae detection than assays targeting the P1 protein or ATPase genes.
Some reference laboratories offer PCR assays that they developed themselves for detection of current mycoplasmal infection. Two molecular-based tests for detection of M pneumoniae are now FDA-approved for use in the United States. One of these is the illumigene Mycoplasma assay (Meridian Bioscience, Inc.). This loop-mediated isothermal amplification (LAMP) assay enables detection of M pneumoniae in up to 10 clinical specimens that can be tested simultaneously within one hour after extracted DNA is set up in the incubator/reader. The multiplex Biofire Diagnostics FilmArray RP detects nucleic acids in nasopharyngeal swabs for 20 respiratory tract pathogens, including M pneumoniae, processing one sample at a time, with results in about an hour .
Carriage of mycoplasmas in the upper respiratory tract for variable periods following prior infection may confound the interpretation of a single positive PCR assay result. Furthermore, a PCR assay may reveal very small numbers of organisms that may not be of etiologic significance.
A specific threshold of quantity of mycoplasmas in the respiratory tract that can differentiate colonization from infection has not been established, so a highly sensitive detection method such as PCR performed in a nonquantitative manner may overestimate the clinical importance of M pneumoniae as a pathogen since it often cocirculates with other bacterial and viral respiratory pathogens. For these reasons, molecular-based assays can be accompanied by serological assays for maximum diagnostic accuracy unless testing a normally sterile body fluid in which the presence of any number of mycoplasmas would be considered evidence of disease. Newer quantitative real-time PCR assays alleviate this problem to some degree.
Given the significant limitations of serology, prolonged turnaround time and insensitivity of culture, and the growing availability of rapid diagnosis of mycoplasmal infection in symptomatic patients by molecular-based assays, molecular-based tests are now the preferred method for diagnosis of M pneumoniae infection when available to primary care physicians through a hospital or reference laboratory.
Abnormalities on chest radiographs often appear more severe than predicted based on the clinical condition of the patient.
Lobar consolidation is unusual.
Diffuse or interstitial infiltrates that involve the lower lobes are the most common radiographic abnormalities.
Small pleural effusions may develop in approximately 20% of cases.
Lung involvement tends to be unilateral but can be bilateral.
Muir MT, Cohn SM, Louden C, Kannan TR, Baseman JB. Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia. Chest. 2011 Feb. 139(2):305-10. [Medline].
Kannan TR, Provenzano D, Wright JR, Baseman JB. Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun. 2005 May. 73(5):2828-34. [Medline].
Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains. Am J Respir Crit Care Med. 2010 Sep 15. 182(6):797-804. [Medline].
Hardy RD, Coalson JJ, Peters J, Chaparro A, Techasaensiri C, Cantwell AM. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PLoS One. 2009. 4(10):e7562. [Medline].
Talkington DF, Waites KB, Schwartz S, Besser RE. Emerging from obscurity: Understanding pulmonary and extrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. Scheld WM, Craig WA, Hughes JM, eds. Emerging Infections. Washington, DC: ASM Press; 2001. Vol 5: 57-84.
Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis. 1993 Aug. 17 Suppl 1:S37-46. [Medline].
Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997 Aug 11-25. 157(15):1709-18. [Medline].
Waites KB. New concepts of Mycoplasma pneumoniae infections in children. Pediatr Pulmonol. 2003 Oct. 36(4):267-78. [Medline].
Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May. 12 Suppl 3:12-24. [Medline].
Cunha BA. Pneumonia Essentials. 3rd ed. Royal Oak, MI: Physicians Press; 2010.
Cunha BA. Liver involvement with Mycoplasma pneumoniae community-acquired pneumonia. J Clin Microbiol. Jul/2003. 41(7):3456-7. [Medline].
Parchuri S, Cunha BA. Mycoplasma pneumoniae community-acquired pneumonia: Diagnostic usefulness of the agglutination-dissociation test. Infect Dis Pract. 2006. 30:550-1.
Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol. 2004 Sep. 11(5):862-7. [Medline].
Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol. 2005 May. 43(5):2277-85. [Medline].
Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol. 2008 Sep. 46(9):3116-8. [Medline].
Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother. 2009 May. 53(5):2160-2. [Medline]. [Full Text].
Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J. 2009 Aug. 28(8):693-6. [Medline].
Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009 Jul. 64(1):52-8. [Medline].
Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother. 2008 Oct. 52(10):3542-9. [Medline]. [Full Text].
Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006 Feb. 50(2):709-12. [Medline].
Klausner JD, Passaro D, Rosenberg J, et al. Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis. 1998 Jan. 177(1):161-6. [Medline].
Ou G, Liu Y, Tang Y, You X, Zeng Y, Xiao J, et al. In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae. Hippokratia. 2015 Jan-Mar. 19 (1):57-62. [Medline].